Aileron Therapeutics, Inc. announced on May 15, 2024, the board of directors of the company appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (Danforth), as interim chief financial officer, effective as of May 16, 2024. In connection with his appointment, Mr. Cunningham will serve as the company's principal financial officer and principal accounting officer, replacing Charles Garner in such roles following Mr. Garner's departure from the company on May 15, 2024. Mr. Cunningham will provide interim chief financial officer services pursuant to a consulting agreement to which the Company is a party with Danforth.

Under the consulting agreement, the Company will pay Danforth an agreed upon hourly rate for Mr. Cunningham's services and will reimburse Danforth for expenses. The consulting agreement may be terminated by the Company or Danforth with cause, upon 30 days written notice, and without cause, upon 60 days written notice. Mr. Cunningham, age 62, has served as Chief Financial Officer Consultant at Danforth, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies.

Mr. Cunningham has served as chief financial officer for Bionomics Limited since May 2023, and he previously served as acting chief financial officer for Peak Bio, Inc. from September 2022 to January 2024 and for SAB Biotherapeutics, Inc. from October 2020 to December 2021. Prior to joining Danforth, Mr. Cunningham served as chief financial officer at Organogenesis from July 2016 to August 2020. Prior to joining Organogenesis, Mr. Cunningham held leadership positions with several different public and private companies over the course of his career, which began at KPMG LLP followed by PricewaterhouseCoopers LLP.

Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida.